BioNTech, Trims

BioNTech Trims German Footprint While Paying $205 Million for Faster FDA Review

Published on 11/22/2026 at 11:31 | Editorial boerse-global.de
BioNTech plans to end manufacturing at three German sites by 2028 and cut about 40 Mainz jobs, while paying $205 million for a priority FDA review voucher.
BioNTech Trims German Footprint While Paying $205 Million for Faster FDA Review Illustration mit AI erstellt.

BioNTech is preparing to wind down production at three German sites and cut roughly 40 jobs at its Mainz headquarters, even as it spends $205 million in cash to buy its way into a faster US regulatory lane for a late-stage cancer drug.

Citing information from Handelsblatt, the company plans to close its manufacturing operations in Marburg, Idar-Oberstein and Tübingen by the end of 2028. Business Insider reported that the Mainz reductions come on top of some 1,800 positions already earmarked for elimination at other locations.

The same magazine flagged unresolved questions surrounding the planned departure of founders U?ur ?ahin and Özlem Türeci. Open items also include how staff will be transferred and how patent arrangements will be handled.

Should investors sell immediately? Or is it worth buying BioNTech?

A Priority Review Voucher for the Pipeline

On the deal front, BioNTech has agreed with Scholar Rock to acquire a voucher granting priority FDA review, at a purchase price of $205 million in cash. The company intends to apply it to a future marketing application for a cancer medicine from its late-stage pipeline. Closing is subject to customary conditions, including antitrust clearance under the HSR process.

Analysts Split on Where the Stock Heads

November brought conflicting moves on valuation. H.C. Wainwright cut its price target to $110 from $130 on 9 November while keeping a buy rating. J.P. Morgan's Jessica Fye, by contrast, nudged her target up to $93 from $92 on Thursday and maintained a neutral stance.

Two further research houses reaffirmed their buy calls on 11 and 17 November, leaving targets unchanged in a range of $108 to $125. The shares nonetheless slipped 5.0% over a seven-day stretch.

Ad

BioNTech Stock: New Analysis - 22 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

Disclaimer...
en | US09075V1026 | BIONTECH | boerse | 70544134 |